SPECIAL NOTICE
A -- Biomarkers of Neurological Injury for the Encephalitic Alphaviruses
- Notice Date
- 5/5/2021 1:31:26 PM
- Notice Type
- Special Notice
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- NAVAL MEDICAL LOGISTICS COMMAND FORT DETRICK MD 21702-9203 USA
- ZIP Code
- 21702-9203
- Solicitation Number
- ADVFYRD100006
- Response Due
- 5/20/2021 1:30:00 PM
- Archive Date
- 06/04/2021
- Point of Contact
- Cheryl Vendemia, Phone: 301-619-6004
- E-Mail Address
-
cheryl.r.vendemia.civ@mail.mil
(cheryl.r.vendemia.civ@mail.mil)
- Description
- This procurement requires research support expertise to review and provide guidance on the planning and execution of Banyan Biomarkers� FDA approved assay for acute diagnosis of brain injury. The existing Banyan brain injury platform measures the protein biomarkers ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) in human serum. These protein biomarkers have already been shown to correlate with acute brain injury in humans following a variety of insults including stroke and cardiac arrest. The study will determine if these protein biomarkers can be detected in the serum of human cases of encephalitis due to alphavirus infection and will also determine if these same protein biomarkers can be detected in non-human primates infected with the encephalitic alphaviruses. The Immunodiagnostics Department requires the technical and research support expertise from the University of Florida who has already collected samples from human cases infected with alphaviruses. The overall goal is to identify biomarkers to monitor disease progression, direct treatment, and as reliable end-points to help develop medical countermeasures for the encephalitic alphaviruses. More generally, these studies will establish the first research paradigm to systematically validate the use of blood biomarkers for the clinical diagnosis of brain injury associated with viral infections.�� The research to be conducted under this requirement must use Banyan Biomarkers Brain Trauma Indicator (BTI) kit. This is the only FDA approved assay to measure the protein biomarkers UCH-L1 and GFAP in human serum. Dr. Amy Vittor at the University of Florida is already collaborating with Banyan Biomarkers to use their kit to detect these biomarkers in human serum. Dr. Vittor has expertise in the epidemiology of alphaviruses in South America and has already collected serum from human cases of alphavirus infection. Dr. Vittor�s expertise is needed to evaluate the use of the Banyan BTI assay for diagnosis of brain injury associated with viral infection. The use of any other source would cause substantial delays and completely disrupt the overall effort. Given the extensive knowledge of Dr. Vittor and her unique human serum samples from alphavirus infected patients, the University of Florida is the only source that possesses the intimate knowledge required to utilize the BTI kit with the already collected human serum samples in support of our effort.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/c44a1128b326465bb9237348046c2e83/view)
- Place of Performance
- Address: Gainesville, FL 32611, USA
- Zip Code: 32611
- Country: USA
- Zip Code: 32611
- Record
- SN05991810-F 20210507/210505230110 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |